申请人:Novo Nordisk A/S
公开号:US05182279A1
公开(公告)日:1993-01-26
Novel [1]benzothieno[2,3-b]pyrazine-2,3(1H,4H)-diones or tautomeric forms thereof of the general formula (I) ##STR1## wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 independently represent hydrogen, halogen, alkyl, alkoxy or trifluoromethyl. The compounds are useful for treating a central nervous system ailment associated with the NMDA receptor-associated glycine site.
1-苯并噻吩[2,3-b]吡嗪-2,3(1H,4H)-二酮或其互变异构体,其通用公式为(I)##STR1##,其中R.sup.1、R.sup.2、R.sup.3和R.sup.4独立地代表氢、卤素、烷基、烷氧基或三氟甲基。这些化合物用于治疗与NMDA受体相关甘氨酸位点相关联的中枢神经系统疾病。